SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
QIDP provides five additional years of market exclusivity, and Fast Track expedites the regulatory pathEnrollment completed in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018Initia...
Page (1) of 1 - 05/01/18||
(May 01, 2018)
This article is no longer available,but here are some related topics.
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved